BioCentury | Aug 8, 2011
Product Development

HIV Trojan horse

HIV's ability to hide out in the body in places that drugs can't reach has helped the virus remain resistant to eradication. But Virxsys Corp. thinks its VRX1273 may be able to provide a functional...
BC Week In Review | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

BioCis and Lx Therapies merged to form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president and CEO of Virxsys Corp. (Gaithersburg, Md.), as president and CEO. Laurantis' lead candidates target inflammatory diseases, dermatitis...
BC Week In Review | Oct 4, 2010
Clinical News

Virxsys preclinical data

Prophylactic VRX1116, a simian analog of VRX1273, led to undetectable viral replication in 2 of 5 rhesus macaques at 13 months post-challenge with simian immunodeficiency virus (SIV) and produced stable or increased CD4+ T cell...
BC Week In Review | Aug 9, 2010
Clinical News

Virxsys preclinical data

In rhesus macaques, prophylactic VRX1273 improved immune responses and led to significant control of viral load over the 4 months following challenge with simian immunodeficiency virus (SIV) vs. unvaccinated controls. Additionally, there were no adverse...
BC Week In Review | Jun 7, 2010
Clinical News

Virxsys preclinical data

In a mouse model of HIV, VRX1023 displayed long-term immunogenicity up to 12 months. The HIV-based lentiviral vector that delivers HIV antigens was repeatedly administered without any marked increase of anti-vector neutralizing activity. Data were...
BC Week In Review | May 31, 2010
Clinical News

Lexgenleucel-T: Phase II data

A Phase II trial showed that 10 of 48 patients who received Lexgenleucel-T had circulating antibodies against the gene therapy's lentiviral vector, vesicular stomatitis virus-G (VSV-G), without associated adverse events or effects on the modified...
BC Week In Review | Feb 22, 2010
Clinical News

Virxsys preclinical data

In rhesus monkeys, VRX1023 reduced viral load by 95% following simian immunodeficiency virus (SIV) challenge at 4 months vs. non-vaccinated control monkeys. No adverse reactions in any of the vaccinated monkeys following multiple infusions have...
BC Week In Review | Feb 22, 2010
Clinical News

Lexgenleucel-T: Phase I/II data

Data from an ongoing, U.S. Phase I/II trial showed that VRX496 led to a decrease in viral load in 7 of 8 evaluable HIV-1 infected patients fully suppressed on antiretroviral treatments who underwent scheduled treatment...
BC Innovations | Sep 17, 2009
Cover Story

Rational attack on HIV

An industry-academic partnership has reported the first fruit of an effort to identify new targets for HIV vaccines. 1 The project, spearheaded by the International AIDS Vaccine Initiative , identified a potential weak spot on the...
BC Week In Review | Feb 16, 2009
Clinical News

Lexgenleucel-T: Phase I/II data

Data from an ongoing, open-label Phase I/II trial in 12 HIV-1 infected patients fully suppressed on antiretroviral treatments showed that VRX496-transduced CD4+ T cells traffic to gut lymphoid tissue in most patients and persist there...
Items per page:
1 - 10 of 31
BioCentury | Aug 8, 2011
Product Development

HIV Trojan horse

HIV's ability to hide out in the body in places that drugs can't reach has helped the virus remain resistant to eradication. But Virxsys Corp. thinks its VRX1273 may be able to provide a functional...
BC Week In Review | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

BioCis and Lx Therapies merged to form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president and CEO of Virxsys Corp. (Gaithersburg, Md.), as president and CEO. Laurantis' lead candidates target inflammatory diseases, dermatitis...
BC Week In Review | Oct 4, 2010
Clinical News

Virxsys preclinical data

Prophylactic VRX1116, a simian analog of VRX1273, led to undetectable viral replication in 2 of 5 rhesus macaques at 13 months post-challenge with simian immunodeficiency virus (SIV) and produced stable or increased CD4+ T cell...
BC Week In Review | Aug 9, 2010
Clinical News

Virxsys preclinical data

In rhesus macaques, prophylactic VRX1273 improved immune responses and led to significant control of viral load over the 4 months following challenge with simian immunodeficiency virus (SIV) vs. unvaccinated controls. Additionally, there were no adverse...
BC Week In Review | Jun 7, 2010
Clinical News

Virxsys preclinical data

In a mouse model of HIV, VRX1023 displayed long-term immunogenicity up to 12 months. The HIV-based lentiviral vector that delivers HIV antigens was repeatedly administered without any marked increase of anti-vector neutralizing activity. Data were...
BC Week In Review | May 31, 2010
Clinical News

Lexgenleucel-T: Phase II data

A Phase II trial showed that 10 of 48 patients who received Lexgenleucel-T had circulating antibodies against the gene therapy's lentiviral vector, vesicular stomatitis virus-G (VSV-G), without associated adverse events or effects on the modified...
BC Week In Review | Feb 22, 2010
Clinical News

Virxsys preclinical data

In rhesus monkeys, VRX1023 reduced viral load by 95% following simian immunodeficiency virus (SIV) challenge at 4 months vs. non-vaccinated control monkeys. No adverse reactions in any of the vaccinated monkeys following multiple infusions have...
BC Week In Review | Feb 22, 2010
Clinical News

Lexgenleucel-T: Phase I/II data

Data from an ongoing, U.S. Phase I/II trial showed that VRX496 led to a decrease in viral load in 7 of 8 evaluable HIV-1 infected patients fully suppressed on antiretroviral treatments who underwent scheduled treatment...
BC Innovations | Sep 17, 2009
Cover Story

Rational attack on HIV

An industry-academic partnership has reported the first fruit of an effort to identify new targets for HIV vaccines. 1 The project, spearheaded by the International AIDS Vaccine Initiative , identified a potential weak spot on the...
BC Week In Review | Feb 16, 2009
Clinical News

Lexgenleucel-T: Phase I/II data

Data from an ongoing, open-label Phase I/II trial in 12 HIV-1 infected patients fully suppressed on antiretroviral treatments showed that VRX496-transduced CD4+ T cells traffic to gut lymphoid tissue in most patients and persist there...
Items per page:
1 - 10 of 31